<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="38545">Rosuvastatin</z:chebi> is known to reduce <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>)-cholesterol and improve endothelial function </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering, <z:chebi fb="0" ids="35664">statins</z:chebi> may exert pleiotropic (nonlipid lowering) effects on microvascular function </plain></SENT>
<SENT sid="2" pm="."><plain>We compared the neurophysiological and vascular responses of dietary control and treatment with 10 mg of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> in 16 subjects with <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> and established type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Skin blood flow (SkBF) measurements were measured at baseline, after 18 weeks of diet, and after 18 weeks of diet and treatment with <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> in response to local warming and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>The study results show that total cholesterol (196.50 ± 8.02 to 134.88 ± 10.86 mg/dL) and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (114 ± 10.4 to 63.4 ± 8.48 mg/dL) decreased significantly after 18 weeks of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi>, but not after 18 weeks of diet </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> scores decreased from 8.34 ± 1.26 at baseline to 6.00 ± 0.90 after <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Basal SkBF was significantly different from baseline, 6.81 ± 0.42 to 9.92 ± 0.78 after <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> treatment (P ≤ 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicate that <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> therapy positively changed basal SkBF and measures of neurovascular function </plain></SENT>
<SENT sid="8" pm="."><plain>Although there was a profound <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering, it is not clear that this mediated the increases in SkBF and decreases in <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> scores </plain></SENT>
</text></document>